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Abstract
Carcinosarcoma of the lung is a malignant tumor composed of a mixture of carcinoma and sarcoma elements. The
carcinomatous component is most commonly squamous followed by adenocarcinoma. The sarcomatous compo-
nent commonly comprises the bulk of the tumor and shows poorly differentiated spindle cell features. Foci of dif-
ferentiated sarcomatous elements such as chondrosarcoma and osteosarcoma may be seen. Aspergillus
pneumonia is the most common form of invasive aspergillosis and occurs mainly in patients with malignancy,
immunocompromizing or debilitating diseases. Patients with Aspergillus pneumonia present with fever, cough,
chest pain and occasionally hemoptysis. Tissue examination is the most reliable method for diagnosis, and mortal-
ity rate is high.
We describe a case of primary carcinosarcoma of the lung concurrently occurring with invasive pulmonary asper-
gillosis in a 66-year old patient.
Background
Primary carcinosarcoma of the lung is exceedingly rare
[1-8]. In the new World Health Organization (WHO)
classification of lung tumors, it is described as malig-
nancy composed of a mixture of carcinoma and sarcoma
elements. The sarcomatous is usually spindle cell but
m a yc o n t a i nc a r t i l a g e ,b o n eo rs k e l e t a lm u s c l ec o m p o -
nents. However, controversy exists in the classification
of this tumor and some authors may include sarcoma-
toid carcinoma in this category.
Invasive pulmonary aspergillosis is a spectrum of reac-
tions that depend on a combination of patient immuno-
logic status, underlying lung condition and the nature of
exposure to aspergillus fungus. It most often presents as
aspergillus pneumonia and almost always involves
immunoecompromized or debilitated patients with
underlying malignancy [9]. Acute leukemia patients are
very susceptible particularly during times of neutrope-
nia. Patients with cirrhosis, chronic obstructive pulmon-
ary disease (COPD), autoimmune deficiency syndrome
(AIDS) and prolonged steroid treatment are at increased
risk. Here we report a case of primary pulmonary carci-
nosarcoma with synchronous aspergillous pneumonia in
a patient with previous prostate cancer. On review of
the literature, this combination has not been reported
before.
Case Report
A 66 years old African American man presented to the
hospital with 1 week history of progressive shortness of
breath and bilateral calf pain. He complained of occa-
sional productive cough but denied any chest pain,
hemoptysis, night sweats, palpitation, or dyspnea. He
had a history of peripheral vascular disease and prostate
cancer Gleason’s score 6(3+3) about 8 years ago for
which he had prostatectomy and subsequent penile
implant for erectile dysfunction. He had an extensive
smoking history but no alcohol or street drug abuse.
Furthermore, he had a prior 8-year history of incarcera-
tion and a family history of lung cancer.
Due to his chest symptoms, he had a chest x-ray fol-
l o w e db yC o m p u t e r i z e dT o m o g r a p h y( C T )s c a no ft h e
chest which showed a left upper lung mass (4.5 × 5.5 ×
5 cm) with mediastinal and right hilar adenopathy
[Fig.1]. No pleural or pericardial effusion was noted. CT
of the head and bone scan revealed no metastasis.
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left lung mass showed inflammatory necrotic back-
ground with several large aggregates of fungi. On
Gomori Methanamine Silver (GMS) stain, the hyphae
had uniform diameter, septation and branching at 45
degree, morphologically compatible with aspergillus spe-
cies [Fig. 2]. A special stain for Acid Fast Bacilli (AFB)
was negative, and no tumor cells were identified. Based
on these findings, he was commenced on liposomal
Amphotericin B for 2 weeks followed by Voriconazole
to complete a 6 week course of antifungal therapy for
pulmonary aspergillosis. His hemoglobin was 7.7 g/dl,
white blood cell count 7.7 k/mm
3, and absolute neutro-
phil, monocyte and lymphocyte count of 4.6 k/mm
3,0 . 6
k/mm
3 and 3.2 k/mm
3 respectively. Serum creatinine
was 1.4 mg/dl and blood urea nitrogen 14 mg/dl. HIV
and Hepatitis C serology were negative. He improved
and was discharged on voriconazole. However, he pre-
sented again after about 8 weeks with new onset
hemoptysis and night sweats. He subsequently had
bronchoscopy with bronchoalveolar lavage (BAL) which
returned negative for mycobacterium, fungus, legionella
and cytomegalovirus on culture. Direct Fluorescent
Antibody of BAL fluid was negative for Parainfluenza 1,
Adenovirus, Herpes Simplex I&II, Respiratory Syncytial
Virus, Varicella Zoster Influenza A&B and Adenovirus.
BAL fluid was negative for malignant cells and Pneumo-
cystis carinii.
Pulmonary function test showed an obstructive pat-
tern (FEV1/FVC ratio 58% of reference). He subse-
quently had a thoracotomy with a left upper lobectomy
revealing biphasic malignant tumor (carcinosarcoma).
Pathology description
A left upper lobectomy (20 × 15.5 × 5.5 cm) was done.
Sectioning revealed a large tan-white circumscribed
partly hemorrhagic mass with central necrotic cavity.
The mass was abutting the pleural surface and measured
8 . 5×6 . 5×5 . 5c mo fw h i c hi n t r a - o p e r a t i v ef r o z e ns e c -
tion was diagnosed as poorly differentiated squamous
cell carcinoma. Interestingly, final surgical pathology
examination revealed a poorly differentiated biphasic
malignant neoplasm with epithelial and spindle cell
components and necrosis [Fig. 3]. The carcinomatous
component showed predominantly squamous cell differ-
entiation with foci of aborted glandular structures. The
sarcomatous component displayed interlacing short fas-
cicles of malignant spindle cells with areas of marked
cellular pleomorphism and bizarre giant tumor cells.
Numerous atypical mitoses and large areas of geo-
graphic necrosis were evident. Morphologically, the dif-
ferential included poorly differentiated lung carcinoma
with “sarcomatoid” growth pattern, primary pulmonary
carcinosarcoma and biphasic poorly differentiated
Figure 1 A CT scan with contrast of the chest showing large
left upper lobe lung mass involving the pleural surface.
Figure 2 A GMS stain showing aspergillus fungal hyphae with
uniform septated hyphae, and branching at 45 degrees (×100,
Gomori Methanamine Silver stain).
Figure 3 Carcinosarcoma with areas of sarcomatous spindle
cell proliferation (left) and an epithelial carcinoma component
(right). (×100, Hematoxylin and Eosin).
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face and the surgical bronchial margin. An extensive
panel of immunostains was performed for further classi-
fication and more precise diagnosis. The epithelial carci-
nomatous tumor cells showed strong immunoreactivity
with pankeratin AE1/AE3 (Fig. 4) and epithelial mem-
brane antigen (EMA) (Fig. 5) and focally for P63; while
vimentin stain was strongly positive in the spindle cell
component but not in the carcinomatous component
[Fig. 6]. Patchy foci of spindle tumor cells were reactive
for calponin and smooth muscle actin. All other mar-
kers including desmin, cKit (CD117), S100 protein, CD
34, HMB45, bcl2, and CD99 were negative essentially
excluding synovial sarcoma. Also, Fluorescence In-situ
Hybridization (FISH) analysis did not detect t(X;18)
translocations of the SYT/18q11.2 region that are char-
acteristic of synovial sarcoma.
Within the resection specimen areas of infarction and
coagulative necrosis were identified, some of them bor-
dering viable tumor (Fig. 7). In one such area, fungal
hyphae morphologically consistent with aspergillus spe-
cies were seen and confirmed by GMS fungal stain
(Fig. 8). Furthermore, shadow outlines of destructed
blood vessels were noted in the infarcted areas.
Additionally, intraoperatively obtained pleural fluid
showed many malignant cells arranged in sheets and
single cell pattern. The tumor cells were round to spin-
dle and highly pleomorphic. Immunostains for CK 5/6,
CK 7, CK 20, TTF-1, CD 15 and CD 30 were all nega-
tive in the tumor cells.
Unfortunately, our patient had a complicated postopera-
tive course in the intensive care unit. He developed pneu-
monia with Acinetobacter and was difficult to wean him
from the ventilator. He finally succumbed to cardiac arrest.
Figure 4 Epithelial carcinoma component of the tumor positive
for cytokeratin AE1/AE3 immunostain (×100).
Figure 5 Epithelial carcinoma component of the tumor
showing positivity for epithelial membrane antigen
immunostain (EMA) (×100).
Figure 6 Sarcoma component of the tumor showing spindle
tumor cells positive for vimentin (×400).
Figure 7 An area of the tumor showing hemorrhagic infarction
and shadow outlines of destructed blood vessels (×100,
Hematoxylin and Eosin).
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Pulmonary carcinosarcoma is a malignant tumor with a
mixture of carcinoma and sarcoma [1,2]. In the WHO
classification of lung tumors, it is included in a group of
poorly differentiated non-small cell lung carcinomas
that contain a component of sarcomatoid differentiation,
so called sarcomatoid carcinoma. The average age of
diagnosis is 60 years with men to women ratio of 4:1
and more than 90% of these patients have a history of
heavy smoking [2]. Pulmonary carcinosarcoma accounts
for < 1% of all primary pulmonary neoplasms [6].
The carcinomatous component is more often squa-
mous cell carcinoma, followed by adenocarcinoma and
large cell carcinoma; whereas the most common
mesenchymal component is poorly differentiated spindle
cell sarcoma. Nevertheless, foci of rhabdomyosarcoma,
osteosarcoma, and chondrosarcoma are often found [3].
In a retrospective analysis of 2,400 lung cancer
patients between 1975 and 1995 conducted by Huwer H
et al, only seven patients (0.3%) had pulmonary carcino-
sarcoma [4]. Diaconita reported eight cases among 3000
patients with malignant pulmonary tumors [5].
Immunohistochemical (IHC) staining enhances the
distinction of carcinomatous from sarcomatous compo-
nents within the tumor. When heterologous sarcoma
elements such as cartilage or skeletal muscle are pre-
s e n t ,i ti se a s i e rt oc o n f i r mt h eb i p h a s i cn a t u r eo ft h e
tumor, although immunostains can be of further help
such as Myogenin and Myo D1 (rhabdomyosarcoma);
smooth muscle actin and desmin (leiomyosarcoma); and
S100 (chondrosarcoma). However, carcinosarcomas are
difficult to diagnose preoperatively. Biopsy of the tumor,
especially when centrally located, often shows only one
component, and peripheral tumors are difficult to reach
endoscopically [4].
Histogenetically, Carcinosarcomas may represent
malignant epithelial neoplasms undergoing divergent tis-
sue differentiation originating from a single clone [7].
The prognosis of these patients is unfavorable based on a
small number of cases described in literature. Ishida et al
reported a 9-month median survival of 5 patients [8].
Davis et al reported a 12 month median survival time in
15 patients post resection [6]. Huwer et al reviewed seven
patients with pulmonary carcinosarcoma out of 2,400
cases of lung cancers and found that mortality was
related to tumor recurrence or distant metastasis of the
sarcoma component [4]. In a clinicopathologic study,
Koss et al retrospectively reviewed 66 patients with pul-
monary carcinosarcoma from the archives of the Armed
Forces Institute of Pathology (AFIP), and compared them
to 33 cases of pleomorphic carcinoma and found that
carcinosarcomas had poor prognosis with a 5-year survi-
val rate of 21.3%. Of several clinical and pathologic para-
meters, only tumor size (6 cm or more) appeared to be
related to reduced survival (p = 0.0195) [3].
Invasive Aspergillosis, is a major cause of morbidity
and mortality in the severely immunocompromised. Risk
factors include prolonged and severe neutropenia, hema-
topoietic stem cell and solid organ transplantation,
advanced AIDS, and chronic granulomatous disease [9].
It is rarely found in patients with solid tumors and in
the absence of the afore mentioned major risks factors.
In retrospective microbiology studies of patients with
“proven” and “probable” invasive aspergillosis based on
the European Organization for Research and Treatment
of Cancer, and the Mycosis Study Group of the National
Institute of Allergy and Infectious Diseases criteria
between 1993-2003, only 1 of a total of 13 patients who
met the criteria for invasive aspergillosis was found to
have lung cancer [10-12]. Steroid use and lymphopenia
were common risk factors among the patients with solid
tumors and invasive aspergilosis [10]. An autopsy review
at M. D. Anderson Caner Center of 588 patients with
hematologic malignancies and 144 patients with solid
tumors done between 1993-2002 revealed that 102
(17.3%) had hematologic malignancies, while only 1
patient (0.68%) had solid tumor (p < 0.01) [10]. The
findings of this studies, as in our case, are in agreement
with previous studies that invasive aspergillosis is much
more common in patients with hematologic than in
solid malignancies.
Nivoix Y et al retrospectively analyzed 289 patients
with presentation that fulfilled the criteria for possible,
probable, or proven invasive aspergillosis according
to the international definitions. The predictors of
increased overall mortality were in patients who received
allogenic hematopoietic stem cell or solid-organ trans-
plant, prior respiratory disease, corticosteroid therapy,
Figure 8 Groups of aspergillus fungal hyphae are present in an
area of hemorrhagic infarction in the resected specimen (×400,
Gomori Methanamine Silver stain).
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aspergillosis, diffuse pulmonary lesions, pleural effusion,
and proven or probable aspergillosis [11].
In our case, the invasive aspergillosis and the subse-
quently diagnosed carcinosarcoma occupied the same
location of the left upper lobe. The typical tissue reac-
tion in aspergillus pneumonia is known to be hemorrha-
gic infarction with a sparse inflammatory infiltrate [13],
and our case revealed similar features. In addition,
despite complete course of antifungal therapy, occa-
sional foci of residual aspergillus hyphae were identified
in such areas of hemorrhagic infarction.
In conclusion, the combination of invasive aspergillo-
sis and solid malignancies is an extremely rare occur-
rence. To the best of our knowledge, there has not been
any reported case of pulmonary carcinosarcoma and
invasive aspergillosis in the literature. Furthermore, this
case report is significant because the patient did not
have any of the commonly described risk factors for
developing invasive aspergillosis. Limited studies found
in literature have shown poor prognosis in patients with
either invasive aspergillosis or pulmonary carcinosar-
coma. Whether the coexistence of these two entities in
a patient increases mortality remains to be determined
in case series, retrospective or prospective studies.
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